Abstract
Prostate tumors initially regress in response to androgen-ablation therapy. However, most cancers eventually relapse with an androgen-depletion-independent (ADI) phenotype that is often more aggressive than the original androgen-dependent (AD) tumor. Importantly, most relapsed tumors still rely upon androgen receptor (AR) activity for proliferation and survival. The cellular Fas/FasL-associated death domain protein-like inhibitory protein (FLIP) inhibits activation of procaspase-8 by death receptor-mediated signaling at the cell surface. In the current study, we examined the androgenic regulation of FLIP and its contribution to protecting prostate cancer cells from death receptor-mediated apoptosis. FLIP expression in tissues from intact and castrated rats as well as androgen-treated prostate cancer cell lines (LNCaP, C4-2, LNCaP-Rf, and DU-145) was monitored via Real-Time RT-PCR and immunoblot. Induction of apoptosis by TRAIL, the death receptor ligand, was determined via microscopic observation and cell counting of fragmented nuclei following fixation and staining with Hoechst 33285. FLIP mRNA and protein expression was reduced following castration in multiple rat tissues, including dorsolateral prostate and seminal vesicles....Continue Reading
References
Jul 11, 1997·The Journal of Biological Chemistry·S HuV M Dixit
Jul 10, 1997·Nature·M IrmlerJ Tschopp
Apr 14, 1999·Cell Death and Differentiation·D M RasperD W Nicholson
Mar 30, 2001·The Journal of Biological Chemistry·A NesterovA S Kraft
Oct 11, 2001·Oncogene·X ChenR K Srivastava
Jun 18, 2003·Journal of Cellular Physiology·Kent L NastiukJohn J Krolewski
Aug 2, 2003·Molecular and Cellular Endocrinology·Hannelore HeemersJohannes V Swinnen
Dec 23, 2003·Journal of Cellular Biochemistry·Natalya V GusevaMichael B Cohen
Mar 12, 2004·Steroids·A F SantosD J Tindall
Sep 25, 2004·The Prostate·Hiroshi MiyamotoChawnshang Chang
Oct 7, 2004·Cancer Research·Xiaoping ZhangAria F Olumi
Oct 8, 2004·The New England Journal of Medicine·Jose D Debes, Donald J Tindall
Jan 12, 2005·The Journal of Urology·R E Sobel, M D Sadar
Feb 11, 2005·The Journal of Biological Chemistry·Alexander GolksInna N Lavrik
Feb 26, 2005·Molecular Endocrinology·Shen GaoZhengxin Wang
Apr 19, 2005·Critical Reviews in Immunology·Takao Kataoka
May 18, 2005·Prostate Cancer and Prostatic Diseases·J KangF Chen
Mar 7, 2006·Journal of Cellular Biochemistry·Scott M Dehm, Donald J Tindall
Mar 17, 2006·The Prostate·Vincent HesryThierry Guillaudeux
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Oct 3, 2007·Expert Opinion on Therapeutic Targets·Delphine MérinoOlivier Micheau
Citations
Oct 1, 2010·Apoptosis : an International Journal on Programmed Cell Death·Wei WangDing Ma
Aug 28, 2012·Apoptosis : an International Journal on Programmed Cell Death·Claudia GiampietriElio Ziparo
Feb 14, 2013·Cancer Letters·Diping WangDonald J Tindall
Feb 5, 2011·Molecular Endocrinology·Jennifer S DavisJohn J Krolewski
Mar 26, 2013·PloS One·Christian L BarrettKelly A Frazer
Jun 15, 2011·Nature Reviews. Urology·Christina Voelkel-Johnson
Jan 3, 2016·Advanced Drug Delivery Reviews·Kent L Nastiuk, John J Krolewski
Jan 11, 2011·Cancer Letters·Marco de BruynWijnand Helfrich
Nov 26, 2015·Biochemical Pharmacology·Marília I FigueiraSílvia Socorro
Dec 17, 2014·Cancer Cell International·Jonghyun HanSung-Hoon Kim
Mar 25, 2010·The Prostate·Giovanni Luca GravinaClaudio Festuccia
Aug 26, 2015·Journal of Medicinal Chemistry·Ya-Ming XuA A Leslie Gunatilaka
Mar 2, 2021·The Journal of Steroid Biochemistry and Molecular Biology·Iván Flores-RamírezElizabeth Langley
Mar 7, 2021·Cancers·Amaal Ali, George Kulik